Coya Therapeutics, Inc. (COYA) – What Are Investment Firms Saying About This Stock?

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.33.

Several brokerages have weighed in on COYA. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research note on Friday, September 25th. Roth Capital reissued a “buy” rating and issued a $12.00 price target on shares of Coya Therapeutics in a research note on Monday, August 24th. Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, August 12th. BTIG Research restated a “buy” rating and issued a $16.00 price objective on shares of Coya Therapeutics in a report on Tuesday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Thursday, October 15th.

Coya Therapeutics Trading Down 3.7%

NASDAQ COYA opened at $3.11 on Wednesday. The stock has a market cap of $72.96 million, a PE ratio of -2.91 and a beta of 0.70. Coya Therapeutics has a twelve month low of $3.03 and a twelve month high of $6.62. The stock has a fifty day simple moving average of $4.54 and a 200-day simple moving average of $4.63.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.07. The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. Research analysts predict that Coya Therapeutics will post -1.34 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in COYA. Allworth Financial LP boosted its holdings in Coya Therapeutics by 1,200.0% during the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after acquiring an additional 12,000 shares during the period. AXQ Capital LP purchased a new position in shares of Coya Therapeutics in the second quarter valued at approximately $116,000. Long Corridor Asset Management Ltd acquired a new position in shares of Coya Therapeutics in the second quarter valued at approximately $227,000. ADAR1 Capital Management LLC acquired a new stake in Coya Therapeutics during the 1st quarter worth approximately $161,000. Finally, Renaissance Technologies LLC boosted its position in Coya Therapeutics by 55.4% in the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after buying an additional 37,064 shares during the period. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction.

The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.